{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:17:55Z","timestamp":1790835475468,"version":"4.1.0"},"reference-count":65,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sphingosine 1 phosphate receptor (S1PR) modulators are the latest drug class to have received approval for the treatment of ulcerative colitis, and have brought a new mechanism of action to this landscape. They target immune cell trafficking, specifically the egress of lymphocytes from lymph nodes to the bloodstream, and have proven to be an efficacious and safe anti-inflammatory mechanism. This narrative review aims to distil the key trial data on the efficacy and safety of ozanimod and etrasimod, the two S1PR modulators currently licensed for use in UC. We discuss the higher response rates in the advanced therapy naive versus exposed subgroups. We summarise their safety profiles, taking into consideration open label extension data. Finally, we consider where this class of drugs may be best placed in the treatment landscape and also provide a practical guide for their use in clinical practice.<\/jats:p>","DOI":"10.3390\/jcm14103475","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:02:27Z","timestamp":1747306947000},"page":"3475","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1978-4430","authenticated-orcid":false,"given":"Xin Yi","family":"Choon","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0256-6895","authenticated-orcid":false,"given":"Jie Han","family":"Yeo","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University College London Hospitals, London NW1 2PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"White","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-9200","authenticated-orcid":false,"given":"Mark A.","family":"Samaan","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative Colitis in Adults: A Review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"ref_2","unstructured":"(2025, March 05). Bristol Myers Squibb. Bristol Myers Squibb Receives European Commission Approval of Zeposia (Ozanimod) for Use in Adults with Moderately to Severely Active Ulcerative Colitis. 23 November 2021. Available online: https:\/\/news.bms.com\/news\/details\/2021\/Bristol-Myers-Squibb-Receives-European-Commission-Approval-of-Zeposia-ozanimod-for-use-in-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis\/default.aspx#:~:text=The%20European%20Commission%20approved%20Zeposia,imaging%20features%20in%20May%202020.&text=ZEPOSIA%20(ozanimod)%20is%20indicated%20for,1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40263-015-0261-z","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis","volume":"29","author":"Subei","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_4","unstructured":"Pfizer (2025, March 05). European Commission Approves Pfizer\u2019s VELSIPITY\u00ae for Patients with Moderately to Severely Active Ulcerative Coliti. 19 February 2024. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/european-commission-approves-pfizers-velsipityr-patients."},{"key":"ref_5","first-page":"417","article-title":"Positioning Sphingosine-1 Phosphate Receptor Modulators in Inflammatory Bowel Disease","volume":"20","author":"Sands","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MEG.0000000000001031","article-title":"Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: A time trade-off study","volume":"30","author":"Holko","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.molmed.2017.02.002","article-title":"Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease","volume":"23","author":"Nielsen","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1093\/ecco-jcc\/jjx107","article-title":"Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration","volume":"12","author":"Danese","year":"2018","journal-title":"J. Crohns Colitis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/med.22044","article-title":"An overview of sphingosine-1-phosphate receptor 2: Structure, biological function, and small-molecule modulators","volume":"44","author":"Hao","year":"2024","journal-title":"Med. Res. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, N., Li, J.Y., Zeng, B., and Chen, G.L. (2023). Sphingosine-1-Phosphate Signaling in Cardiovascular Diseases. Biomolecules, 13.","DOI":"10.3390\/biom13050818"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zou, F., Wang, S., Xu, M., Wu, Z., and Deng, F. (2023). The role of sphingosine-1-phosphate in the gut mucosal microenvironment and inflammatory bowel diseases. Front. Physiol., 14.","DOI":"10.3389\/fphys.2023.1235656"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/apt.16741","article-title":"Review article: The sphingosine 1 phosphate\/sphingosine 1 phosphate receptor axis\u2014A unique therapeutic target in inflammatory bowel disease","volume":"55","author":"Wang","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_13","first-page":"265","article-title":"Sphingosine-1 Phosphate Receptor Modulators: The Next Wave of Oral Therapies in Inflammatory Bowel Disease","volume":"18","author":"Choden","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/CEG.S43453","article-title":"S1pping fire: Sphingosine-1- phosphate signaling as an emerging target in inflammatory bowel disease and colitis associated cancer","volume":"7","author":"Saba","year":"2014","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2011.05.005","article-title":"Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy","volume":"142","author":"Ingwersen","year":"2012","journal-title":"Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dal Buono, A., Gabbiadini, R., Alfarone, L., Solitano, V., Repici, A., Vetrano, S., Spinelli, A., and Armuzzi, A. (2022). Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071735"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00415-013-7115-8","article-title":"Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study","volume":"261","author":"Gold","year":"2014","journal-title":"J. Neurol."},{"key":"ref_18","first-page":"e41520","article-title":"Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103680","DOI":"10.1016\/j.msard.2022.103680","article-title":"Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis","volume":"59","author":"Askari","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14656566.2022.2071605","article-title":"An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis","volume":"23","author":"Rowan","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the First-in-Human Study with Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator","volume":"57","author":"Tran","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/10600280211041907","article-title":"Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis","volume":"56","author":"Choi","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","unstructured":"(2022). Rapidity of Ozanimod-Induced Symptomatic Response and Remission in Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Induction Period of True North. Gastroenterol. Hepatol., 18, 2\u20133."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.cgh.2024.03.042","article-title":"Ozanimod in Patients with Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies","volume":"22","author":"Sands","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_28","first-page":"3310","article-title":"Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial","volume":"10","author":"Sands","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"i110","DOI":"10.1093\/ecco-jcc\/jjac190.0083","article-title":"DOP43 Extended induction in the True North OLE study: Ozanimod efficacy in biologic-naive and biologic-experienced patients","volume":"17","author":"Dignass","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ecco-jcc\/jjad112","article-title":"Clinician\u2019s Guide to Using Ozanimod for the Treatment of Ulcerative Colitis","volume":"17","author":"Sands","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results from the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension","volume":"18","author":"Danese","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cgh.2023.11.018","article-title":"Cardiovascular Safety of Ozanimod in Patients with Ulcerative Colitis: True North and Open-Label Extension Analyses","volume":"22","author":"Armuzzi","year":"2024","journal-title":"Clin. Gastro. Hep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S921","DOI":"10.14309\/01.ajg.0001034520.61834.16","article-title":"Real-World Effectiveness of Ozanimod for Ulcerative Colitis in Patients with Prior Advanced Therapy Exposure: A Multicenter Study","volume":"119","author":"Scalzo","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10620-023-08178-8","article-title":"Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center","volume":"69","author":"Cohen","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.14309\/01.ajg.0001082608.37890.a2","article-title":"Real-World Efficacy and Safety of Ozanimod in US Patients with Moderately to Severely Active Ulcerative Colitis: Initial Results from POLARIS, an Ongoing Phase 4 Open-Label Study","volume":"119","author":"Abraham","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Qiu, J., Liu, J., Cai, K., Xu, T., Liu, W., Lin, F., and Shi, N. (2024). Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1420455"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/CEG.S391706","article-title":"Therapeutic Potential of Etrasimod in the Management of Moderately-to-Severely Active Ulcerative Colitis: Evidence to Date","volume":"17","author":"Glassner","year":"2024","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjae038","article-title":"Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme","volume":"18","author":"Dubinsky","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/ecco-jcc\/jjae079","article-title":"Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials","volume":"18","author":"Vermeire","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_43","unstructured":"(2025, March 05). A Study to Learn About the Effectiveness of Etrasimod in People with Ulcerative Colitis (EFFECT-UC), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06294925?cond=ulcerative%20colitis&intr=etrasimod&rank=4."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bencardino, S., D\u2019Amico, F., Faggiani, I., Bernardi, F., Allocca, M., Furfaro, F., Parigi, T.L., Zilli, A., Fiorino, G., and Peyrin-Biroulet, L. (2023). Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155014"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.21037\/atm-21-6679","article-title":"Sphingosine 1-phosphate receptor 1 governs endothelial barrier function and angiogenesis by upregulating endoglin signaling","volume":"10","author":"Wang","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_47","unstructured":"EMA (2025, March 05). Zeposia. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zeposia."},{"key":"ref_48","unstructured":"EMA (2025, March 05). Velsipity. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/velsipity."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00415-021-10910-1","article-title":"Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: An updated review of literature","volume":"269","author":"Sriwastava","year":"2022","journal-title":"J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Monfared, N., Gold, M., Carbery, I., Laube, R., and Selinger, C.P. (2024). Reproductive safety issues of novel small molecules for the treatment of inflammatory bowel disease: A systematic review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010034"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1093\/ibd\/izae011","article-title":"Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients with Ulcerative Colitis, Crohn\u2019s Disease, and Relapsing Multiple Sclerosis","volume":"30","author":"Dubinsky","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S1032","DOI":"10.14309\/01.ajg.0001035116.14492.4e","article-title":"S1437 Pregnancy Outcomes in the Etrasimod Clinical Program","volume":"119","author":"Gecse","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2468-1253(24)00386-8","article-title":"Tamuzimod in patients with moderately-to-severely active ulcerative colitis: A multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial","volume":"10","author":"Sands","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"i1592","DOI":"10.1093\/ecco-jcc\/jjae190.1008","article-title":"P0834 Mucosal improvement and histologic healing with amiselimod for active Ulcerative Colitis: A phase 2, randomised, placebo-controlled trial","volume":"19","author":"Schreiber","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_55","unstructured":"(2025, March 05). Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03440372."},{"key":"ref_56","unstructured":"(2025, March 05). A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants with Moderately to Severely Active Crohn\u2019s Disease (CULTIVATE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04173273#more-information."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis","volume":"17","author":"Solitano","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jcag\/gwae013","article-title":"Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies","volume":"7","author":"Jairath","year":"2024","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohn\u2019s Colitis 360"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e240225","DOI":"10.57264\/cer-2024-0225","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: Systematic literature review and Bayesian network meta-analysis","volume":"14","author":"Jairath","year":"2025","journal-title":"J. Comp. Eff. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/17474124.2021.1898944","article-title":"Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration","volume":"15","author":"Denesh","year":"2021","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs. small molecules: Drug costs and patient access","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"106584","DOI":"10.1016\/j.prostaglandins.2021.106584","article-title":"Role of sphingosine-1-phosphate mediated signalling in systemic lupus erythematosus","volume":"156","author":"Tian","year":"2021","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_65","first-page":"922","article-title":"S1P\/S1PR signaling pathway advancements in autoimmune diseases","volume":"23","author":"Li","year":"2023","journal-title":"Biomol. Biomed."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3475\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:33:30Z","timestamp":1760031210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":65,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14103475"],"URL":"https:\/\/doi.org\/10.3390\/jcm14103475","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}